DTIL
NASDAQPrecision BioSciences Inc.
Price$7.86-0.29 (-3.62%)
01:30 PM07:45 PM
News · 26 weeks56-77%
2026-01-182026-07-12
Mix3190d
- Insider14(45%)
- Other9(29%)
- SEC Filings6(19%)
- Earnings1(3%)
- Analyst1(3%)
Latest news
25 items- PRPrecision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that, on July 5, 2026, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan ("Inducement Award Plan"). The inducement awards consist of an aggregate total of 114,622 restricted stock units ("RSUs"), granted among three employees in connection with their commencement of employment. Each award was granted under Nasdaq Listing Rule
- SECPrecision BioSciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)
- PRPrecision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional InvestorsPrecision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced its addition to the Russell 2000® Index, effective at the close of U.S. equity markets on June 26, 2026, according to the final list of additions published by FTSE Russell. The annual reconstitution of the Russell U.S. indexes ranks eligible U.S. stocks by total market capitalization. Membership in the Russell 2000® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for it
- SECPrecision BioSciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)
- ANALYSTOppenheimer initiated coverage on Precision BioSciences with a new price targetOppenheimer initiated coverage of Precision BioSciences with a rating of Outperform and set a new price target of $20.00
- INSIDERSEC Form 4 filed by Director Brown Melinda4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERSEC Form 4 filed by Director Frankel Stanley4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERSEC Form 4 filed by Director Germano Geno J4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERSEC Form 4 filed by Director Pire Shari Lisa4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERSEC Form 4 filed by Director Buehler Kevin4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERSEC Form 4 filed by Chief Research Officer Smith J. Jefferson4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Kelly John Alexander4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERSEC Form 4 filed by General Counsel and Secretary Scimeca Dario4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERSEC Form 4 filed by President and CEO Amoroso Michael4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- SECPrecision BioSciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)
- SECPrecision BioSciences Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)
- INSIDERDirector Buehler Kevin converted options into 21,000 shares, increasing direct ownership by 75% to 49,137 units (SEC Form 4)4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERDirector Frankel Stanley converted options into 21,000 shares, increasing direct ownership by 108% to 40,478 units (SEC Form 4)4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERDirector Brown Melinda converted options into 21,000 shares, increasing direct ownership by 90% to 44,346 units (SEC Form 4)4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERDirector Pire Shari Lisa converted options into 21,000 shares, increasing direct ownership by 150% to 35,028 units (SEC Form 4)4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- INSIDERDirector Germano Geno J converted options into 21,000 shares, increasing direct ownership by 88% to 44,883 units (SEC Form 4)4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
- PRiECURE Reports Sustained Clinical Response in the First Patient Dosed with ECUR-506 & Reductions in the Annualized Rates of Hyperammonemic Events and Crises in the First Completed Cohort of ECUR-506 in Ongoing OTC-HOPE TrialFirst infant treated in the low-dose cohort achieved durable clinical response with sustained discontinuation of standard-of-care therapies, and no hyperammonemic events (HAEs) reported in the 18 months following administration of ECUR-506 Statistically significant reductions in the annualized rate of HAEs and hyperammonemic crises (HACs) observed in the completed low-dose cohort (n=3), with 57% (p =0.018) and 65% (p =0.011) reductions, respectively, in pre-dose to post-dose rates of events per person-year Data presented at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic in vivo t
- PRPrecision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting– New preclinical data show PBGENE-DMD drove up to a 3x higher dystrophin protein restoration in skeletal muscle and up to 12x higher in respiratory muscle in early-juvenile mice compared to late-juvenile mice – – Findings further support evaluation of PBGENE-DMD in DMD patient populations as young as 2 years of age – – Greater efficacy with earlier intervention further differentiates PBGENE-DMD from microdystrophin approaches – Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced new preclinical data from its PBGENE-DMD pr
- PRiECURE Presents Preliminary Clinical Data from Ongoing Clinical Trial of ECUR-506 in Ornithine Transcarbamylase Deficiency at the ASGCT Annual MeetingPreliminary data from participants enrolled in three dose cohorts (n=7) demonstrate that 71% of participants experienced no hyperammonemic crises (HACs) following ECUR-506 treatment, as of the April 20, 2026 data cutoff date. HACs are defined as plasma ammonia levels above 100µmol/L with neurologic status change. Data from these cohorts also demonstrate approximately 52% reduction in the annualized rate of HACs following ECUR-506 administration. HACs are the most clinically significant neurometabolic manifestation of ornithine transcarbamylase (OTC) deficiency. Reducing or preventing these crises is a key treatment goal, clinically meaningful measure of patient benefit, and an im
- SECSEC Form 10-Q filed by Precision BioSciences Inc.10-Q - PRECISION BIOSCIENCES INC (0001357874) (Filer)
DTIL FAQ
7 questionsWhat does Precision BioSciences Inc. do?
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic anti-CD19 CAR T cell product candidate for the patients with relapsed or refractory, or R/R, non-Hodgkin...Where does DTIL stock trade?
Precision BioSciences Inc. (DTIL) is listed on NASDAQ.What sector and industry is DTIL in?
Precision BioSciences Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Precision BioSciences Inc. go public?
Precision BioSciences Inc. (DTIL) completed its IPO in 2019.What are analysts saying about DTIL?
Precision BioSciences Inc. has had 6 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform with a $2000.00 price target on 2026-06-09. Recent price targets range from $700.00 to $3400.00.What companies are similar to DTIL?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare DTIL side-by-side with any of them on Quantisnow.How can I track DTIL on Quantisnow?
Quantisnow aggregates Precision BioSciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DTIL to receive live email and push alerts on every new disclosure.